Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.
Bristol Myers Squibb is asking shareholders at its virtual May 5, 2026 meeting to elect 11 directors, approve an advisory say‑on‑pay vote, adopt a 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as auditor, and consider a proposal for an independent board chair.
The proxy highlights 2025 execution: the Growth Portfolio generated $26.4 billion in sales, up 17% over 2024, with seven products annualizing above $1 billion. The company reports 18 global regulatory approvals, completion of a $10 billion debt paydown target ahead of schedule, and a dividend raised for the 16th consecutive year.
Board materials emphasize strong governance, with 10 of 11 director nominees independent, active board refreshment, majority voting with resignation policies, extensive risk oversight, and integration of sustainability and social impact goals into strategy and executive incentives, including expanded use of AI in R&D and operations.
Bristol Myers Squibb executive Hiroshi Chris Shibutani, EVP and Chief Strategy Officer, received equity-based compensation awards in the form of derivatives tied to the company’s common stock. On March 10, 2026, he was granted 7,837 Market Share Units and 11,755 Performance Shares at a price of $0.00 per unit.
Each market share unit represents a target number of shares that can convert into common stock based on a payout factor linked to total shareholder return and a relative TSR floor, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to the Board certifying performance results, and carry an expiration date of March 10, 2029.
Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to certification of performance results by the Board. After these grants, reported holdings for these awards are 7,837 market share units and 11,755 performance shares, respectively.
Massacesi Cristian reported acquisition or exercise transactions in this Form 4 filing.
Bristol Myers Squibb executive Cristian Massacesi received new performance-based equity awards. On March 10, 2026, he was granted 26,122 Market Share Units and 39,184 Performance Shares, each tied to the company’s common stock. The Market Share Units cliff vest after three years, while payouts for both awards depend on Total Return and relative total shareholder return performance through around 2029.
Bristol Myers Squibb EVP Wendy Short Bartie reported multiple equity-related transactions in connection with long-term incentive awards. On March 10, 2026, she exercised market share units and performance shares, receiving a total of 5,883 shares of common stock through derivative conversions.
She also received new grants of 6,531 market share units and 9,796 performance share units that are subject to future performance certification and vesting, generally around 2029. To cover tax obligations upon vesting, 1,275 common shares were withheld at $60.13 per share.
After these transactions and related performance-based adjustments, she directly holds 7,917 shares of Bristol Myers Squibb common stock, in addition to the newly granted performance-based units. The filing reflects routine compensation vesting, new awards, and associated tax withholding rather than open-market buying or selling.